Mary Ann Anderson

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Joanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, Chia Sharpe, Piers Blombery, Mary Ann Anderson, Andrew W Roberts, John F Seymour, Constantine S Tam, David S Ritchie, Rachel M Koldej

Journal article  |  2020  |  Blood Advances

Combination venetoclax plus ibrutinib for the treatment of mantle cell lymphoma (MCL) has demonstrated efficacy in the relapsed or..

BTK inhibitor therapy is effective in patients with CLL resistant to venetoclax

Victor S Lin, Thomas E Lew, Sasanka M Handunnetti, Piers Blombery, Tamia Nguyen, David A Westerman, Bryone J Kuss, Constantine S Tam, Andrew W Roberts, John F Seymour, Mary Ann Anderson

Journal article  |  2020  |  Blood

Highly active BTK inhibitors (BTKis) and the BCL2 inhibitor venetoclax have transformed the therapeutic landscape for chronic lymp..

Undetectable minimal residual disease should be the goal of venetoclax therapy in relapsed and refractory chronic lymphocytic leukaemia

Thomas Lew, Mary Ann Anderson, Victor Lin, Sasanka Handunnetti, Neil Came, David Westerman, Wall Meaghan, Constantine Tam, Andrew W Roberts, John F Seymour

Conference Proceedings  |  2020  |  LEUKEMIA & LYMPHOMA

Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 months

Thomas E Lew, Mary Ann Anderson, Victor S Lin, Sasanka M Handunnetti, Neil A Came, Piers Blombery, David A Westerman, Meaghan Wall, Constantine S Tam, Andrew W Roberts, John F Seymour

Journal article  |  2020  |  Blood Advances

The highly selective BCL2 inhibitor venetoclax achieves deep responses in patients with relapsed or refractory (R/R) chronic lymph..

Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax

Piers Blombery, Ella Thompson, Nguyen Tamia, Xiangting Chen, Michelle McBean, Richard W Birkinshaw, Peter E Czabotar, Rachel Thijssen, Mary Ann Anderson, John F Seymour, David Alan Westerman, David CS Huang, Andrew W Roberts

Conference Proceedings  |  2019  |  Blood

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations

Richard W Birkinshaw, Jia-nan Gong, Cindy S Luo, Daisy Lio, Christine A White, Mary Ann Anderson, Piers Blombery, Guillaume Lessene, Ian J Majewski, Rachel Thijssen, Andrew W Roberts, David CS Huang, Peter M Colman, Peter E Czabotar

Journal article  |  2019  |  Nature Communications

Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia

Piers Blombery, Mary Ann Anderson, Jia-nan Gong, Rachel Thijssen, Richard W Birkinshaw, Ella R Thompson, Charis E Teh, Tamia Nguyen, Zhen Xu, Christoffer Flensburg, Thomas E Lew, Ian J Majewski, Daniel HD Gray, David A Westerman, Constantine S Tam, John F Seymour, Peter E Czabotar, David CS Huang, Andrew W Roberts

Journal article  |  2019  |  Cancer Discovery

Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma

Rishu Agarwal, Yih-Chih Chan, Constantine S Tam, Tane Hunter, Dane Vassiliadis, Charis E Teh, Rachel Thijssen, Paul Yeh, Stephen Q Wong, Sarah Ftouni, Enid YN Lam, Mary Ann Anderson, Christiane Pott, Omer Gilan, Charles C Bell, Kathy Knezevic, Piers Blombery, Kathleen Rayeroux, Adrian Zordan, Jason Li, et al.

Journal article  |  2019  |  Nature Medicine